nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Doxorubicin—testicular cancer	0.749	1	CbGbCtD
Lubiprostone—CLCN2—seminal vesicle—testicular cancer	0.0217	0.256	CbGeAlD
Lubiprostone—CLCN2—gonad—testicular cancer	0.0157	0.185	CbGeAlD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.013	0.457	CbGpPWpGaD
Lubiprostone—CLCN2—testis—testicular cancer	0.0113	0.133	CbGeAlD
Lubiprostone—CBR1—seminal vesicle—testicular cancer	0.00872	0.103	CbGeAlD
Lubiprostone—Dinoprostone—HPGDS—testicular cancer	0.00867	1	CrCbGaD
Lubiprostone—CLCN2—lymph node—testicular cancer	0.00821	0.0966	CbGeAlD
Lubiprostone—CBR1—Vincristine—Vinblastine—testicular cancer	0.0065	1	CbGdCrCtD
Lubiprostone—CBR1—gonad—testicular cancer	0.0063	0.0741	CbGeAlD
Lubiprostone—CBR1—NRF2 pathway—SLC2A6—testicular cancer	0.00551	0.193	CbGpPWpGaD
Lubiprostone—CBR1—female gonad—testicular cancer	0.00512	0.0603	CbGeAlD
Lubiprostone—CBR1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00471	0.165	CbGpPWpGaD
Lubiprostone—CBR1—testis—testicular cancer	0.00454	0.0534	CbGeAlD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00412	0.144	CbGpPWpGaD
Lubiprostone—CBR1—lymph node—testicular cancer	0.00329	0.0387	CbGeAlD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000674	0.0236	CbGpPWpGaD
Lubiprostone—Feeling abnormal—Bleomycin—testicular cancer	0.000432	0.00355	CcSEcCtD
Lubiprostone—Vomiting—Chlorambucil—testicular cancer	0.000431	0.00353	CcSEcCtD
Lubiprostone—Anorexia—Ifosfamide—testicular cancer	0.000427	0.0035	CcSEcCtD
Lubiprostone—Malaise—Cisplatin—testicular cancer	0.000427	0.0035	CcSEcCtD
Lubiprostone—Decreased appetite—Dactinomycin—testicular cancer	0.000425	0.00349	CcSEcCtD
Lubiprostone—Diarrhoea—Vinblastine—testicular cancer	0.000425	0.00349	CcSEcCtD
Lubiprostone—Dysgeusia—Etoposide—testicular cancer	0.000425	0.00348	CcSEcCtD
Lubiprostone—Fatigue—Dactinomycin—testicular cancer	0.000422	0.00346	CcSEcCtD
Lubiprostone—Pain—Dactinomycin—testicular cancer	0.000418	0.00343	CcSEcCtD
Lubiprostone—Muscle spasms—Etoposide—testicular cancer	0.000417	0.00342	CcSEcCtD
Lubiprostone—Lethargy—Epirubicin—testicular cancer	0.000412	0.00338	CcSEcCtD
Lubiprostone—Dizziness—Vinblastine—testicular cancer	0.000411	0.00337	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000408	0.00335	CcSEcCtD
Lubiprostone—Myalgia—Cisplatin—testicular cancer	0.000403	0.00331	CcSEcCtD
Lubiprostone—Feeling abnormal—Dactinomycin—testicular cancer	0.000403	0.00331	CcSEcCtD
Lubiprostone—Nausea—Chlorambucil—testicular cancer	0.000403	0.0033	CcSEcCtD
Lubiprostone—Ill-defined disorder—Etoposide—testicular cancer	0.000403	0.0033	CcSEcCtD
Lubiprostone—Anxiety—Cisplatin—testicular cancer	0.000402	0.0033	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.0004	0.00328	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Dactinomycin—testicular cancer	0.0004	0.00328	CcSEcCtD
Lubiprostone—Dyspnoea—Ifosfamide—testicular cancer	0.0004	0.00328	CcSEcCtD
Lubiprostone—Discomfort—Cisplatin—testicular cancer	0.000398	0.00327	CcSEcCtD
Lubiprostone—Vomiting—Vinblastine—testicular cancer	0.000395	0.00324	CcSEcCtD
Lubiprostone—Malaise—Etoposide—testicular cancer	0.000391	0.00321	CcSEcCtD
Lubiprostone—Decreased appetite—Ifosfamide—testicular cancer	0.00039	0.0032	CcSEcCtD
Lubiprostone—Headache—Vinblastine—testicular cancer	0.000389	0.00319	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000387	0.00317	CcSEcCtD
Lubiprostone—Abdominal pain—Dactinomycin—testicular cancer	0.000387	0.00317	CcSEcCtD
Lubiprostone—Fatigue—Ifosfamide—testicular cancer	0.000386	0.00317	CcSEcCtD
Lubiprostone—Oedema—Cisplatin—testicular cancer	0.000386	0.00317	CcSEcCtD
Lubiprostone—Hypersensitivity—Bleomycin—testicular cancer	0.000386	0.00317	CcSEcCtD
Lubiprostone—Constipation—Ifosfamide—testicular cancer	0.000383	0.00314	CcSEcCtD
Lubiprostone—Pain—Ifosfamide—testicular cancer	0.000383	0.00314	CcSEcCtD
Lubiprostone—Loss of consciousness—Etoposide—testicular cancer	0.000381	0.00313	CcSEcCtD
Lubiprostone—Lethargy—Doxorubicin—testicular cancer	0.000381	0.00313	CcSEcCtD
Lubiprostone—Nervous system disorder—Cisplatin—testicular cancer	0.000379	0.00311	CcSEcCtD
Lubiprostone—Cough—Etoposide—testicular cancer	0.000379	0.0031	CcSEcCtD
Lubiprostone—Tachycardia—Cisplatin—testicular cancer	0.000377	0.00309	CcSEcCtD
Lubiprostone—Asthenia—Bleomycin—testicular cancer	0.000376	0.00309	CcSEcCtD
Lubiprostone—Skin disorder—Cisplatin—testicular cancer	0.000375	0.00308	CcSEcCtD
Lubiprostone—Hyperhidrosis—Cisplatin—testicular cancer	0.000374	0.00306	CcSEcCtD
Lubiprostone—Feeling abnormal—Ifosfamide—testicular cancer	0.000369	0.00303	CcSEcCtD
Lubiprostone—Chest pain—Etoposide—testicular cancer	0.000369	0.00303	CcSEcCtD
Lubiprostone—Nausea—Vinblastine—testicular cancer	0.000369	0.00303	CcSEcCtD
Lubiprostone—Anorexia—Cisplatin—testicular cancer	0.000368	0.00302	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000367	0.00301	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000367	0.00301	CcSEcCtD
Lubiprostone—Discomfort—Etoposide—testicular cancer	0.000365	0.00299	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000364	0.00298	CcSEcCtD
Lubiprostone—Hypersensitivity—Dactinomycin—testicular cancer	0.00036	0.00296	CcSEcCtD
Lubiprostone—Abdominal discomfort—Methotrexate—testicular cancer	0.000358	0.00293	CcSEcCtD
Lubiprostone—Gastritis—Epirubicin—testicular cancer	0.000357	0.00293	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000356	0.00292	CcSEcCtD
Lubiprostone—Abdominal pain—Ifosfamide—testicular cancer	0.000354	0.00291	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000352	0.00289	CcSEcCtD
Lubiprostone—Abdominal distension—Epirubicin—testicular cancer	0.000351	0.00288	CcSEcCtD
Lubiprostone—Asthenia—Dactinomycin—testicular cancer	0.000351	0.00288	CcSEcCtD
Lubiprostone—Influenza—Epirubicin—testicular cancer	0.000349	0.00286	CcSEcCtD
Lubiprostone—Tachycardia—Etoposide—testicular cancer	0.000346	0.00283	CcSEcCtD
Lubiprostone—Dyspnoea—Cisplatin—testicular cancer	0.000345	0.00283	CcSEcCtD
Lubiprostone—Skin disorder—Etoposide—testicular cancer	0.000344	0.00282	CcSEcCtD
Lubiprostone—Hyperhidrosis—Etoposide—testicular cancer	0.000342	0.00281	CcSEcCtD
Lubiprostone—Anorexia—Etoposide—testicular cancer	0.000337	0.00277	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000336	0.00276	CcSEcCtD
Lubiprostone—Decreased appetite—Cisplatin—testicular cancer	0.000336	0.00276	CcSEcCtD
Lubiprostone—Diarrhoea—Dactinomycin—testicular cancer	0.000335	0.00275	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000334	0.00274	CcSEcCtD
Lubiprostone—Vomiting—Bleomycin—testicular cancer	0.000333	0.00274	CcSEcCtD
Lubiprostone—Rash—Bleomycin—testicular cancer	0.000331	0.00271	CcSEcCtD
Lubiprostone—Gastritis—Doxorubicin—testicular cancer	0.000331	0.00271	CcSEcCtD
Lubiprostone—Pain—Cisplatin—testicular cancer	0.00033	0.00271	CcSEcCtD
Lubiprostone—Dermatitis—Bleomycin—testicular cancer	0.00033	0.00271	CcSEcCtD
Lubiprostone—Hypersensitivity—Ifosfamide—testicular cancer	0.00033	0.00271	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00033	0.0027	CcSEcCtD
Lubiprostone—Abdominal distension—Doxorubicin—testicular cancer	0.000325	0.00267	CcSEcCtD
Lubiprostone—Influenza—Doxorubicin—testicular cancer	0.000323	0.00265	CcSEcCtD
Lubiprostone—Pollakiuria—Epirubicin—testicular cancer	0.000322	0.00264	CcSEcCtD
Lubiprostone—Asthenia—Ifosfamide—testicular cancer	0.000322	0.00264	CcSEcCtD
Lubiprostone—Feeling abnormal—Cisplatin—testicular cancer	0.000318	0.00261	CcSEcCtD
Lubiprostone—Weight increased—Epirubicin—testicular cancer	0.000318	0.0026	CcSEcCtD
Lubiprostone—Dyspnoea—Etoposide—testicular cancer	0.000316	0.00259	CcSEcCtD
Lubiprostone—Nausea—Bleomycin—testicular cancer	0.000312	0.00256	CcSEcCtD
Lubiprostone—Vomiting—Dactinomycin—testicular cancer	0.000311	0.00255	CcSEcCtD
Lubiprostone—Rash—Dactinomycin—testicular cancer	0.000308	0.00253	CcSEcCtD
Lubiprostone—Decreased appetite—Etoposide—testicular cancer	0.000308	0.00252	CcSEcCtD
Lubiprostone—Diarrhoea—Ifosfamide—testicular cancer	0.000307	0.00252	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Etoposide—testicular cancer	0.000306	0.00251	CcSEcCtD
Lubiprostone—Fatigue—Etoposide—testicular cancer	0.000305	0.0025	CcSEcCtD
Lubiprostone—Pain—Etoposide—testicular cancer	0.000303	0.00248	CcSEcCtD
Lubiprostone—Constipation—Etoposide—testicular cancer	0.000303	0.00248	CcSEcCtD
Lubiprostone—Urinary tract infection—Epirubicin—testicular cancer	0.000302	0.00248	CcSEcCtD
Lubiprostone—CBR1—Metabolism—HPGDS—testicular cancer	0.0003	0.0105	CbGpPWpGaD
Lubiprostone—Pollakiuria—Doxorubicin—testicular cancer	0.000298	0.00245	CcSEcCtD
Lubiprostone—Dizziness—Ifosfamide—testicular cancer	0.000296	0.00243	CcSEcCtD
Lubiprostone—Weight increased—Doxorubicin—testicular cancer	0.000294	0.00241	CcSEcCtD
Lubiprostone—Feeling abnormal—Etoposide—testicular cancer	0.000292	0.00239	CcSEcCtD
Lubiprostone—Nausea—Dactinomycin—testicular cancer	0.000291	0.00238	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Etoposide—testicular cancer	0.00029	0.00237	CcSEcCtD
Lubiprostone—Vomiting—Ifosfamide—testicular cancer	0.000285	0.00234	CcSEcCtD
Lubiprostone—Hypersensitivity—Cisplatin—testicular cancer	0.000285	0.00234	CcSEcCtD
Lubiprostone—Rash—Ifosfamide—testicular cancer	0.000283	0.00232	CcSEcCtD
Lubiprostone—Dermatitis—Ifosfamide—testicular cancer	0.000282	0.00232	CcSEcCtD
Lubiprostone—Abdominal pain—Etoposide—testicular cancer	0.00028	0.0023	CcSEcCtD
Lubiprostone—Urinary tract infection—Doxorubicin—testicular cancer	0.00028	0.0023	CcSEcCtD
Lubiprostone—Asthenia—Cisplatin—testicular cancer	0.000277	0.00227	CcSEcCtD
Lubiprostone—Oedema peripheral—Epirubicin—testicular cancer	0.000275	0.00226	CcSEcCtD
Lubiprostone—Connective tissue disorder—Epirubicin—testicular cancer	0.000275	0.00225	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methotrexate—testicular cancer	0.000269	0.00221	CcSEcCtD
Lubiprostone—Nausea—Ifosfamide—testicular cancer	0.000266	0.00218	CcSEcCtD
Lubiprostone—Diarrhoea—Cisplatin—testicular cancer	0.000264	0.00217	CcSEcCtD
Lubiprostone—Mental disorder—Methotrexate—testicular cancer	0.000262	0.00214	CcSEcCtD
Lubiprostone—Hypersensitivity—Etoposide—testicular cancer	0.000261	0.00214	CcSEcCtD
Lubiprostone—Erythema—Methotrexate—testicular cancer	0.00026	0.00213	CcSEcCtD
Lubiprostone—Malnutrition—Methotrexate—testicular cancer	0.00026	0.00213	CcSEcCtD
Lubiprostone—Oedema peripheral—Doxorubicin—testicular cancer	0.000255	0.00209	CcSEcCtD
Lubiprostone—Dysgeusia—Methotrexate—testicular cancer	0.000254	0.00209	CcSEcCtD
Lubiprostone—Asthenia—Etoposide—testicular cancer	0.000254	0.00208	CcSEcCtD
Lubiprostone—Connective tissue disorder—Doxorubicin—testicular cancer	0.000254	0.00208	CcSEcCtD
Lubiprostone—Mediastinal disorder—Epirubicin—testicular cancer	0.000252	0.00206	CcSEcCtD
Lubiprostone—Vomiting—Cisplatin—testicular cancer	0.000246	0.00202	CcSEcCtD
Lubiprostone—Mental disorder—Epirubicin—testicular cancer	0.000245	0.00201	CcSEcCtD
Lubiprostone—Rash—Cisplatin—testicular cancer	0.000244	0.002	CcSEcCtD
Lubiprostone—Dermatitis—Cisplatin—testicular cancer	0.000243	0.002	CcSEcCtD
Lubiprostone—Malnutrition—Epirubicin—testicular cancer	0.000243	0.00199	CcSEcCtD
Lubiprostone—Erythema—Epirubicin—testicular cancer	0.000243	0.00199	CcSEcCtD
Lubiprostone—Diarrhoea—Etoposide—testicular cancer	0.000242	0.00199	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methotrexate—testicular cancer	0.000241	0.00198	CcSEcCtD
Lubiprostone—Flatulence—Epirubicin—testicular cancer	0.00024	0.00197	CcSEcCtD
Lubiprostone—Dysgeusia—Epirubicin—testicular cancer	0.000238	0.00195	CcSEcCtD
Lubiprostone—Malaise—Methotrexate—testicular cancer	0.000234	0.00192	CcSEcCtD
Lubiprostone—Dizziness—Etoposide—testicular cancer	0.000234	0.00192	CcSEcCtD
Lubiprostone—Muscle spasms—Epirubicin—testicular cancer	0.000234	0.00192	CcSEcCtD
Lubiprostone—Mediastinal disorder—Doxorubicin—testicular cancer	0.000233	0.00191	CcSEcCtD
Lubiprostone—Nausea—Cisplatin—testicular cancer	0.00023	0.00188	CcSEcCtD
Lubiprostone—Cough—Methotrexate—testicular cancer	0.000227	0.00186	CcSEcCtD
Lubiprostone—Mental disorder—Doxorubicin—testicular cancer	0.000226	0.00186	CcSEcCtD
Lubiprostone—Ill-defined disorder—Epirubicin—testicular cancer	0.000226	0.00185	CcSEcCtD
Lubiprostone—Vomiting—Etoposide—testicular cancer	0.000225	0.00185	CcSEcCtD
Lubiprostone—Erythema—Doxorubicin—testicular cancer	0.000225	0.00185	CcSEcCtD
Lubiprostone—Malnutrition—Doxorubicin—testicular cancer	0.000225	0.00185	CcSEcCtD
Lubiprostone—Rash—Etoposide—testicular cancer	0.000223	0.00183	CcSEcCtD
Lubiprostone—Dermatitis—Etoposide—testicular cancer	0.000223	0.00183	CcSEcCtD
Lubiprostone—Headache—Etoposide—testicular cancer	0.000222	0.00182	CcSEcCtD
Lubiprostone—Flatulence—Doxorubicin—testicular cancer	0.000222	0.00182	CcSEcCtD
Lubiprostone—Chest pain—Methotrexate—testicular cancer	0.000221	0.00181	CcSEcCtD
Lubiprostone—Myalgia—Methotrexate—testicular cancer	0.000221	0.00181	CcSEcCtD
Lubiprostone—Dysgeusia—Doxorubicin—testicular cancer	0.00022	0.00181	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00022	0.0018	CcSEcCtD
Lubiprostone—Malaise—Epirubicin—testicular cancer	0.000219	0.0018	CcSEcCtD
Lubiprostone—Discomfort—Methotrexate—testicular cancer	0.000219	0.00179	CcSEcCtD
Lubiprostone—Syncope—Epirubicin—testicular cancer	0.000218	0.00179	CcSEcCtD
Lubiprostone—CBR1—Metabolism—STK11—testicular cancer	0.000218	0.00763	CbGpPWpGaD
Lubiprostone—Muscle spasms—Doxorubicin—testicular cancer	0.000216	0.00177	CcSEcCtD
Lubiprostone—Palpitations—Epirubicin—testicular cancer	0.000215	0.00176	CcSEcCtD
Lubiprostone—Loss of consciousness—Epirubicin—testicular cancer	0.000214	0.00175	CcSEcCtD
Lubiprostone—Cough—Epirubicin—testicular cancer	0.000212	0.00174	CcSEcCtD
Lubiprostone—Nausea—Etoposide—testicular cancer	0.00021	0.00172	CcSEcCtD
Lubiprostone—Ill-defined disorder—Doxorubicin—testicular cancer	0.000209	0.00171	CcSEcCtD
Lubiprostone—Nervous system disorder—Methotrexate—testicular cancer	0.000208	0.00171	CcSEcCtD
Lubiprostone—Chest pain—Epirubicin—testicular cancer	0.000207	0.0017	CcSEcCtD
Lubiprostone—Myalgia—Epirubicin—testicular cancer	0.000207	0.0017	CcSEcCtD
Lubiprostone—Anxiety—Epirubicin—testicular cancer	0.000206	0.00169	CcSEcCtD
Lubiprostone—Skin disorder—Methotrexate—testicular cancer	0.000206	0.00169	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000206	0.00169	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methotrexate—testicular cancer	0.000205	0.00168	CcSEcCtD
Lubiprostone—Discomfort—Epirubicin—testicular cancer	0.000205	0.00168	CcSEcCtD
Lubiprostone—Malaise—Doxorubicin—testicular cancer	0.000203	0.00166	CcSEcCtD
Lubiprostone—Dry mouth—Epirubicin—testicular cancer	0.000202	0.00166	CcSEcCtD
Lubiprostone—Anorexia—Methotrexate—testicular cancer	0.000202	0.00166	CcSEcCtD
Lubiprostone—Syncope—Doxorubicin—testicular cancer	0.000202	0.00165	CcSEcCtD
Lubiprostone—Palpitations—Doxorubicin—testicular cancer	0.000199	0.00163	CcSEcCtD
Lubiprostone—Oedema—Epirubicin—testicular cancer	0.000198	0.00163	CcSEcCtD
Lubiprostone—Loss of consciousness—Doxorubicin—testicular cancer	0.000198	0.00162	CcSEcCtD
Lubiprostone—Cough—Doxorubicin—testicular cancer	0.000196	0.00161	CcSEcCtD
Lubiprostone—Shock—Epirubicin—testicular cancer	0.000195	0.0016	CcSEcCtD
Lubiprostone—Nervous system disorder—Epirubicin—testicular cancer	0.000195	0.0016	CcSEcCtD
Lubiprostone—Tachycardia—Epirubicin—testicular cancer	0.000194	0.00159	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000193	0.00158	CcSEcCtD
Lubiprostone—Skin disorder—Epirubicin—testicular cancer	0.000193	0.00158	CcSEcCtD
Lubiprostone—Hyperhidrosis—Epirubicin—testicular cancer	0.000192	0.00157	CcSEcCtD
Lubiprostone—Chest pain—Doxorubicin—testicular cancer	0.000192	0.00157	CcSEcCtD
Lubiprostone—Myalgia—Doxorubicin—testicular cancer	0.000192	0.00157	CcSEcCtD
Lubiprostone—Anxiety—Doxorubicin—testicular cancer	0.000191	0.00157	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00019	0.00156	CcSEcCtD
Lubiprostone—Discomfort—Doxorubicin—testicular cancer	0.000189	0.00155	CcSEcCtD
Lubiprostone—Anorexia—Epirubicin—testicular cancer	0.000189	0.00155	CcSEcCtD
Lubiprostone—Dyspnoea—Methotrexate—testicular cancer	0.000189	0.00155	CcSEcCtD
Lubiprostone—Dry mouth—Doxorubicin—testicular cancer	0.000187	0.00154	CcSEcCtD
Lubiprostone—Dyspepsia—Methotrexate—testicular cancer	0.000187	0.00153	CcSEcCtD
Lubiprostone—Decreased appetite—Methotrexate—testicular cancer	0.000184	0.00151	CcSEcCtD
Lubiprostone—Oedema—Doxorubicin—testicular cancer	0.000184	0.00151	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000183	0.0015	CcSEcCtD
Lubiprostone—Fatigue—Methotrexate—testicular cancer	0.000183	0.0015	CcSEcCtD
Lubiprostone—Pain—Methotrexate—testicular cancer	0.000181	0.00149	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000181	0.00148	CcSEcCtD
Lubiprostone—Shock—Doxorubicin—testicular cancer	0.000181	0.00148	CcSEcCtD
Lubiprostone—Nervous system disorder—Doxorubicin—testicular cancer	0.00018	0.00148	CcSEcCtD
Lubiprostone—Tachycardia—Doxorubicin—testicular cancer	0.000179	0.00147	CcSEcCtD
Lubiprostone—Skin disorder—Doxorubicin—testicular cancer	0.000178	0.00146	CcSEcCtD
Lubiprostone—Hyperhidrosis—Doxorubicin—testicular cancer	0.000178	0.00146	CcSEcCtD
Lubiprostone—Dyspnoea—Epirubicin—testicular cancer	0.000177	0.00145	CcSEcCtD
Lubiprostone—Anorexia—Doxorubicin—testicular cancer	0.000175	0.00144	CcSEcCtD
Lubiprostone—Feeling abnormal—Methotrexate—testicular cancer	0.000175	0.00143	CcSEcCtD
Lubiprostone—Dyspepsia—Epirubicin—testicular cancer	0.000175	0.00143	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Methotrexate—testicular cancer	0.000173	0.00142	CcSEcCtD
Lubiprostone—Decreased appetite—Epirubicin—testicular cancer	0.000173	0.00141	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000171	0.00141	CcSEcCtD
Lubiprostone—Fatigue—Epirubicin—testicular cancer	0.000171	0.0014	CcSEcCtD
Lubiprostone—Constipation—Epirubicin—testicular cancer	0.00017	0.00139	CcSEcCtD
Lubiprostone—Pain—Epirubicin—testicular cancer	0.00017	0.00139	CcSEcCtD
Lubiprostone—Abdominal pain—Methotrexate—testicular cancer	0.000168	0.00137	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000167	0.00137	CcSEcCtD
Lubiprostone—Dyspnoea—Doxorubicin—testicular cancer	0.000164	0.00134	CcSEcCtD
Lubiprostone—Feeling abnormal—Epirubicin—testicular cancer	0.000164	0.00134	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Epirubicin—testicular cancer	0.000162	0.00133	CcSEcCtD
Lubiprostone—Dyspepsia—Doxorubicin—testicular cancer	0.000162	0.00133	CcSEcCtD
Lubiprostone—Decreased appetite—Doxorubicin—testicular cancer	0.00016	0.00131	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000159	0.0013	CcSEcCtD
Lubiprostone—Fatigue—Doxorubicin—testicular cancer	0.000158	0.0013	CcSEcCtD
Lubiprostone—Constipation—Doxorubicin—testicular cancer	0.000157	0.00129	CcSEcCtD
Lubiprostone—Pain—Doxorubicin—testicular cancer	0.000157	0.00129	CcSEcCtD
Lubiprostone—Abdominal pain—Epirubicin—testicular cancer	0.000157	0.00129	CcSEcCtD
Lubiprostone—Hypersensitivity—Methotrexate—testicular cancer	0.000156	0.00128	CcSEcCtD
Lubiprostone—Asthenia—Methotrexate—testicular cancer	0.000152	0.00125	CcSEcCtD
Lubiprostone—Feeling abnormal—Doxorubicin—testicular cancer	0.000151	0.00124	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00015	0.00123	CcSEcCtD
Lubiprostone—Hypersensitivity—Epirubicin—testicular cancer	0.000146	0.0012	CcSEcCtD
Lubiprostone—Abdominal pain—Doxorubicin—testicular cancer	0.000145	0.00119	CcSEcCtD
Lubiprostone—Diarrhoea—Methotrexate—testicular cancer	0.000145	0.00119	CcSEcCtD
Lubiprostone—Asthenia—Epirubicin—testicular cancer	0.000142	0.00117	CcSEcCtD
Lubiprostone—Dizziness—Methotrexate—testicular cancer	0.00014	0.00115	CcSEcCtD
Lubiprostone—Diarrhoea—Epirubicin—testicular cancer	0.000136	0.00111	CcSEcCtD
Lubiprostone—Hypersensitivity—Doxorubicin—testicular cancer	0.000135	0.00111	CcSEcCtD
Lubiprostone—Vomiting—Methotrexate—testicular cancer	0.000135	0.00111	CcSEcCtD
Lubiprostone—Rash—Methotrexate—testicular cancer	0.000134	0.0011	CcSEcCtD
Lubiprostone—Dermatitis—Methotrexate—testicular cancer	0.000134	0.0011	CcSEcCtD
Lubiprostone—Headache—Methotrexate—testicular cancer	0.000133	0.00109	CcSEcCtD
Lubiprostone—Asthenia—Doxorubicin—testicular cancer	0.000132	0.00108	CcSEcCtD
Lubiprostone—Dizziness—Epirubicin—testicular cancer	0.000131	0.00108	CcSEcCtD
Lubiprostone—Vomiting—Epirubicin—testicular cancer	0.000126	0.00103	CcSEcCtD
Lubiprostone—Nausea—Methotrexate—testicular cancer	0.000126	0.00103	CcSEcCtD
Lubiprostone—Diarrhoea—Doxorubicin—testicular cancer	0.000126	0.00103	CcSEcCtD
Lubiprostone—Rash—Epirubicin—testicular cancer	0.000125	0.00103	CcSEcCtD
Lubiprostone—Dermatitis—Epirubicin—testicular cancer	0.000125	0.00103	CcSEcCtD
Lubiprostone—Headache—Epirubicin—testicular cancer	0.000124	0.00102	CcSEcCtD
Lubiprostone—Dizziness—Doxorubicin—testicular cancer	0.000121	0.000996	CcSEcCtD
Lubiprostone—Nausea—Epirubicin—testicular cancer	0.000118	0.000967	CcSEcCtD
Lubiprostone—Vomiting—Doxorubicin—testicular cancer	0.000117	0.000958	CcSEcCtD
Lubiprostone—Rash—Doxorubicin—testicular cancer	0.000116	0.00095	CcSEcCtD
Lubiprostone—Dermatitis—Doxorubicin—testicular cancer	0.000116	0.000949	CcSEcCtD
Lubiprostone—Headache—Doxorubicin—testicular cancer	0.000115	0.000944	CcSEcCtD
Lubiprostone—Nausea—Doxorubicin—testicular cancer	0.000109	0.000895	CcSEcCtD
